{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T04:26:59Z","timestamp":1766377619609,"version":"3.44.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Despite recent therapeutic advances in chronic lymphocytic leukemia (CLL), access to innovative treatments may still be uneven outside Western Europe. This study aimed to explore reimbursement policy and access to novel targeted CLL therapies across selected countries and to analyze factors associated with differences in treatment availability and reimbursement timelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Reimbursement frameworks, timelines, and accessibility of six novel CLL therapies were assessed across 15 countries in Central and Eastern Europe, the Balkans, Armenia, and Israel. Data were collected via expert surveys in late 2024, based on publicly available national and regional sources. The survey covered reimbursement extent, timelines, policy restrictions, coverage pathways, and health technology assessment (HTA) evaluations. Comparative analyses examined regional differences in reimbursement and their potential drivers. Spearman\u2019s rank correlation was used to explore associations between the number of reimbursed therapies, reimbursement delays, and demographic, macroeconomic, and epidemiological variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The number of reimbursed therapies ranged from zero (Ukraine, Armenia) to five (Czech Republic), with a regional mean of 2.7 (SD = 1.38) and overall mean time to reimbursement of 29.3\u00a0months (SD = 21.4). Ibrutinib, reimbursed in 13 countries, had the longest mean reimbursement delay (35.6\u00a0months), while venetoclax (11 countries, 26.5\u00a0months), acalabrutinib (9 countries, 16.4 months), and zanubrutinib (6 countries, 15.2\u00a0months) had shorter delays. Gross domestic product (GPD) <jats:italic>per capita<\/jats:italic> showed a moderate positive correlation with the number of reimbursed therapies (\u03c1 = 0.673, p = 0.006). Borderline significant associations were noted for CLL incidence and mortality (p = 0.050). Reimbursement indications were often restricted, particularly for patients without deletion 17p or TP53 mutations who experienced late relapses. Data on HTA outcomes and the number of treated patients were limited in several countries, and common challenges included funding constraints, administrative barriers, and the lack of centralized rare disease policies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Significant disparities in access to targeted CLL therapies persist across the analyzed countries, with the number of reimbursed therapies positively correlated with GDP <jats:italic>per capita<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1629465","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:13:58Z","timestamp":1756786438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed\/refractory chronic lymphocytic leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Magdalena","family":"Monica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Becirovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Bianchi-Manaila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasa","family":"Duborija-Kovacevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pero","family":"Draganic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Garouliene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Hammerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanni","family":"Ispan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boryana","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"M\u00e4nnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gergo","family":"Meresz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lusine","family":"Nazaryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleksandra","family":"Oleshchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Savova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Skoupa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Stefanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Tesar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Kawalec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"104282","DOI":"10.1016\/j.lpm.2025.104282","article-title":"Health technology assessment in Europe: a comparison of organizations and introduction to the European regulation","volume":"54","author":"Fernandez","year":"2025","journal-title":"La Presse M\u00e9dicale"},{"key":"B4","volume-title":"Access to oncology medicines in EU and OECD countries","author":"Hofmarcher","year":"2024"},{"key":"B5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4149\/neo_2025_241211n518","article-title":"Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia \u2013 real-world data from a hemato-oncology center","volume":"72","author":"Holasov\u00e1","year":"2025","journal-title":"neo"},{"key":"B6","unstructured":"Global Burden of Disease Study 2021 (GBD 2021) results\n          \n          \n          2022"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.17219\/acem\/99911","article-title":"Ibrutinib discontinuation in patients with relapsed or refractorychronic lymphocytic leukemia treated in acompassionate use program:a report from the Polish Adult Leukemia Study Group (PALG)","volume":"28","author":"Iskierka-Ja\u017cd\u017cewska","year":"2019","journal-title":"Adv. Clin. Exp. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1369178","DOI":"10.3389\/fphar.2024.1369178","article-title":"Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries","volume":"15","author":"Jakubowski","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of Venetoclax-Rituximab in Relapsed\/Refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: Post-Treatment Follow-Up of the MURANO phase III Study","volume":"37","author":"Kater","year":"2019","journal-title":"JCO"},{"key":"B10","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3389\/fphar.2017.00892","article-title":"Pharmaceutical regulation in central and Eastern European countries: a Current review","volume":"8","author":"Kawalec","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.healthpol.2019.05.021","article-title":"Patterns of alternative access: unpacking the Slovak extraordinary drug reimbursement regime 2012-2016","volume":"123","author":"L\u00f6blov\u00e1","year":"2019","journal-title":"Health Policy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3389\/fphar.2018.01263","article-title":"Reimbursement of orphan drugs in Europe in relation to the type of authorization by the European Medicines Agency and the decision making based on health technology assessment","volume":"9","author":"Malinowski","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1158\/1078-0432.CCR-21-1237","article-title":"Recognizing unmet need in the era of targeted therapy for CLL\/SLL: \u201cwhat\u2019s Past Is Prologue\u201d (Shakespeare)","volume":"28","author":"Mato","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/medicina59020324","article-title":"Real-World clinical outcomes and adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib: a single-center retrospective Study","volume":"59","author":"Moldovianu","year":"2023","journal-title":"Medicina"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17588359241285988","DOI":"10.1177\/17588359241285988","article-title":"Comparative safety of novel targeted therapies in relapsed\/refractory chronic lymphocytic leukemia: a network meta-analysis","volume":"16","author":"Monica","year":"","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"17588359241263710","DOI":"10.1177\/17588359241263710","article-title":"Network meta-analysis of novel targeted therapies for relapsed\/refractory chronic lymphocytic leukemia","volume":"16","author":"Monica","year":"","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B17","volume-title":"Chronic lymphocytic leukemia,\u201d in","author":"Mukkamalla","year":"2025"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow\u2010up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"840616","DOI":"10.3389\/fonc.2022.840616","article-title":"Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic Study","volume":"12","author":"Ou","year":"2022","journal-title":"Front. Oncol."},{"key":"B20","unstructured":"Cancer stat facts: leukemia \u2014 chronic Lymphocytic Leukemia (CLL)\n          \n          \n          2024"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s00277-023-05304-4","article-title":"Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia\u2014a real-world analysis of the Polish Adult Leukemia Study Group","volume":"102","author":"Sobo\u0144","year":"2023","journal-title":"Ann. Hematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjh.18736","article-title":"Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed\/refractory chronic lymphocytic leukaemia: a real\u2010world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)","volume":"202","author":"\u0160pa\u010dek","year":"2023","journal-title":"Br. J. Haematol."},{"key":"B25","unstructured":"World Bank open data\n          \n          \n          2021"},{"key":"B26","unstructured":"World Health Organization data\n          \n          \n          2021"},{"key":"B27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13023-019-1078-5","article-title":"Comparing access to orphan medicinal products in Europe","volume":"14","author":"Zamora","year":"2019","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1629465\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:14:03Z","timestamp":1756786443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1629465\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":27,"alternative-id":["10.3389\/fphar.2025.1629465"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1629465","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"article-number":"1629465"}}